Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
News|Videos|July 30, 2024
Outcomes of Larotrectinib Compared With Real-World Data From Non-TRK Inhibitor Therapies in Patients With TRK Fusion Cancer: VICTORIA Study
Author(s)Vivek Subbiah, MD
VICTORIA (NCT05192642), is an exact-matching study comparing the outcomes of patients with TRK fusion cancer treated with larotrectinib in 3 clinical trials (NCT02122913, NCT02576431, NCT02637687) to patients treated with non-TRK inhibitor therapies in the real-world (RW) setting.
Advertisement
Advertisement
Related to this article
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
4
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
5